A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC
Clinical trial NCT03511963 · COMPLETED
Trial details
- NCT number
- NCT03511963
- Sponsor
- Shanghai Henlius Biotech
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-09
- Primary completion
- 2020-04-15
- Enrollment
- 677
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.